Home / FAQ / Pharmacy / What is the “Retained Margin” in Pharmacy Funding?  

What is the “Retained Margin” in Pharmacy Funding?  

The Retained Margin (RM) in UK Pharmacy Funding refers to the portion of the agreed-upon fixed NHS Pharmacy funding pot (the Global Sum) that community pharmacies are expected to earn through the efficient purchasing of generic medicines. It is not a direct fee paid by the NHS, but rather the calculated difference between the price at which the NHS reimburses the pharmacy for a drug and the lower, competitive price at which the pharmacy is able to purchase it from wholesalers. This mechanism incentivises pharmacies to act as cost-saving procurement agents for the NHS, and its delivery is primarily managed via Category M Pricing adjustments.

Mechanism of the Retained Margin (RM)

The Retained Margin is a crucial but inherently complex component of the NHS Community Pharmacy Contractual Framework (CPCF), serving as a primary driver of operational income for dispensing activities.

Category M Pricing and Margin Delivery

The delivery of the collectively agreed Retained Margin (which has historically been around £800 million to £900 million annually for the sector in England) is achieved through specific pricing within the Drug Tariff.

What is Category M pricing and how does it relate to the retained margin calculation?

Category M Pricing is the key adjustment mechanism used by the Department of Health and Social Care (DHSC) to manage the flow of the Retained Margin. Category M sets the official NHS reimbursement price for a large number of readily available generic medicines.

  • Pricing Methodology: Category M prices are set quarterly using data from manufacturers and suppliers regarding the average selling price and volume of these generics. The reimbursement price is intentionally set above the average market purchase price, creating an embedded profit for the pharmacy on every dispensed item—this difference is the Retained Margin.
  • Collective Management: The DHSC closely monitors the total margin delivered across the sector. If pharmacies collectively earn more than the guaranteed Retained Margin (measured through margin surveys), HMRC implements a Clawback mechanism by reducing future Category M reimbursement prices to recoup the excess margin.

Impact on Financial Statements

The Retained Margin represents revenue to the pharmacy and has a direct impact on the Profit and Loss Account.

What impact does the retained margin have on a pharmacy’s profit and loss account?

The Retained Margin is recognised not as a single line item, but as a component of the pharmacy’s Gross Profit from dispensing. It affects the profit and loss account as follows:

  • Revenue Recognition: The NHS reimbursement (based on the Drug Tariff) is recognised as revenue.
  • Cost of Goods Sold (COGS): The actual, lower price paid to the wholesaler is recognised as the COGS.
  • Gross Profit: The difference between the NHS reimbursement (revenue) and the actual purchase cost (COGS) constitutes the Gross Profit, which includes the Retained Margin. A significant portion of the pharmacy’s core profitability is derived from successfully maximising this margin.

Tax and Compliance Treatment of the RM

The Retained Margin, once realised, is treated as ordinary business revenue subject to the standard UK tax regime.

HMRC Taxable Profits Assurance

The Retained Margin directly feeds into the practice’s final tax liability.

How does HMRC treat the Retained Margin for Corporation Tax purposes?

HMRC treats the Retained Margin as normal trading income.

  • Taxable Profits: The entire Gross Profit margin realised on dispensing (which includes the RM) is added to the pharmacy’s other revenue streams (e.g., professional service fees, retail sales). This total is then offset by Allowable Expenses (e.g., staff Payroll, rent) to determine the final Taxable Profits.
  • Corporate vs. Income Tax: For Limited Company pharmacies, these profits are subject to Corporation Tax (CT) (at 19% or 25%). For sole trader/partnership pharmacies, the profits are allocated to the owners and subject to Income Tax (IT) via Self Assessment (SA) Tax Returns.

Regulatory Reporting and Clawback

The Clawback mechanism creates a high degree of financial volatility and risk for the pharmacy sector. This involves adjusting payment schedules, often without contractor-specific accuracy. The profit generated by the RM must be reconciled with the actual payment received from the NHS Scheme Administrator (the NHSBSA or similar bodies in England and Wales).

AZL: Optimising Your Pharmacy’s Retained Margin and Profitability

Managing the Retained Margin requires a sophisticated understanding of both HMRC tax rules and the complex financial mechanics of the CPCF. AZL provides expert Chartered Accountants in England & Wales who specialise in the pharmaceutical sector.

COGS Analysis and Margin Maximisation

We provide forensic analysis to accurately track and maximise the actual profit derived from efficient drug purchasing.

Forensic COGS Analysis: AZL conducts analysis of purchasing invoices against the Drug Tariff reimbursement schedule. We ensure the Cost of Goods Sold (COGS) is accurately reported in the bookkeeping to reflect the lowest achievable price, thereby maximising the legally retained Gross Profit margin.

Regulatory Funding Reconciliation and Clawback Forecasting

We help predict and manage the impact of national funding adjustments on your local pharmacy.

Clawback Forecasting: AZL reconciles the pharmacy’s monthly payment schedule (FP34 statements) against the national Category M Pricing updates. We provide forecasting of potential Clawback impacts, allowing the pharmacy to anticipate cash flow shortfalls and adjust stock purchasing strategies proactively.

HMRC Taxable Profits Assurance

We ensure compliant and optimised tax returns based on accurate margin calculations.

Taxable Profits Integration: AZL guarantees the Retained Margin is correctly incorporated into the calculation of final Taxable Profits for the CT600 (or SA Tax Return), ensuring all deductible Allowable Expenses and Capital Allowances are claimed to minimise the final CT or IT liability.

Integrated Compliance Assurance

Robust margin management is crucial for the long-term viability of the pharmacy business.

  • Bookkeeping Integrity: Our bookkeeping services are tailored to the pharmaceutical sector, providing the essential data trail to reconcile purchasing efficiency with NHS payments.
  • Payroll Stability: By optimising the Retained Margin and forecasting its effect on Gross Profit, we ensure the practice maintains stable cash flow to meet fixed operating expenses, particularly Payroll costs.
  • Inheritance Tax Planning: A stable financial history, underpinned by verifiable RM generation, is essential for a high, defensible business valuation for Inheritance Tax purposes.
Secret Link